"Doxorubicin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
| Descriptor ID |
D004317
|
| MeSH Number(s) |
D02.455.426.559.847.562.050.200.175 D04.615.562.050.200.175 D09.408.051.059.200.175
|
| Concept/Terms |
Adriblastin- Adriblastin
- Adriblastine
- Adriblastina
- Adriablastine
- Adriablastin
DOXO-cell- DOXO-cell
- DOXO cell
- Urokit Doxo-cell
- Urokit Doxo cell
|
Below are MeSH descriptors whose meaning is more general than "Doxorubicin".
Below are MeSH descriptors whose meaning is more specific than "Doxorubicin".
This graph shows the total number of publications written about "Doxorubicin" by people in this website by year, and whether "Doxorubicin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 1996 | 2 | 0 | 2 |
| 1997 | 0 | 1 | 1 |
| 1998 | 1 | 2 | 3 |
| 1999 | 0 | 2 | 2 |
| 2000 | 1 | 0 | 1 |
| 2001 | 2 | 0 | 2 |
| 2002 | 0 | 1 | 1 |
| 2004 | 2 | 1 | 3 |
| 2005 | 1 | 4 | 5 |
| 2006 | 1 | 2 | 3 |
| 2007 | 2 | 1 | 3 |
| 2009 | 1 | 2 | 3 |
| 2010 | 1 | 1 | 2 |
| 2011 | 2 | 4 | 6 |
| 2012 | 0 | 3 | 3 |
| 2013 | 1 | 2 | 3 |
| 2014 | 0 | 6 | 6 |
| 2015 | 2 | 3 | 5 |
| 2016 | 4 | 2 | 6 |
| 2017 | 1 | 4 | 5 |
| 2018 | 2 | 1 | 3 |
| 2019 | 0 | 2 | 2 |
| 2020 | 0 | 3 | 3 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Doxorubicin" by people in Profiles.
-
Outcomes of cardiac diffuse large B-cell lymphoma (DLBCL) in the rituximab era. Int J Cardiol. 2021 Sep 15; 339:146-149.
-
An Electrochemical Strategy for the Simultaneous Detection of Doxorubicin and Simvastatin for Their Potential Use in the Treatment of Cancer. Biosensors (Basel). 2021 Jan 03; 11(1).
-
Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma. BJU Int. 2021 05; 127(5):528-537.
-
Single center analysis of therapy and outcomes of hepatocellular carcinoma in Sub-Saharan Africa. Expert Rev Gastroenterol Hepatol. 2020 Oct; 14(10):1007-1011.
-
Perspectives on chemotherapy for the management of double-hit lymphoma. Expert Opin Pharmacother. 2020 Apr; 21(6):653-661.
-
Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models. Sci Rep. 2019 12 11; 9(1):18882.
-
Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study. Clin Cancer Res. 2020 03 01; 26(5):1000-1008.
-
Developing a Quantitative Ultrasound Image Feature Analysis Scheme to Assess Tumor Treatment Efficacy Using a Mouse Model. Sci Rep. 2019 05 13; 9(1):7293.
-
Improved chemotherapy against breast cancer through immunotherapeutic activity of fucoidan decorated electrostatically assembled nanoparticles bearing doxorubicin. Int J Biol Macromol. 2019 Feb 01; 122:1100-1114.
-
A Spectral Fiedler Field-based Contrast Platform for Imaging of Nanoparticles in Colon Tumor. Sci Rep. 2018 07 30; 8(1):11390.